BioNTech

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account typically reactivates within 24 hours; contact support if still disabled.

Experts discuss notable clinical trials and emerging therapies at the 2024 ESMO Congress, including BioNTech's BNT211-01 trial, the TRIM study on melanoma follow-up, the EA3163 trial's early closure, and novel targets in solid tumors. The importance of reviewing all data, regardless of presentation format, is emphasized.

DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.

GSK sues Moderna for patent infringement on mRNA vaccine technology, claiming Moderna's COVID-19 vaccines rely on GSK's foundational patents from a team led by Christian Mandl at Novartis. GSK seeks damages and licensing fees.

The mRNA therapeutics market is projected to grow from $33.5 billion in 2023 to $40.69 billion by 2028 at a CAGR of 4%, driven by factors like rising infectious diseases, personalized medicine demand, and regulatory support. Key trends include mRNA delivery tech advancements, saRNA platforms, and manufacturing scalability.

UK High Court upheld patent EP 1 893 196 for enzalutamide, rejecting generics' claim of obviousness. The patent, owned by UC Regents and licensed to Astellas, covers the prostate cancer drug Xtandi. Parallel proceedings are pending in Europe.

KEYNOTE-522 trial demonstrated significant overall survival benefit with pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer, with a 5-year survival rate of 86.6% vs 81.7% with chemotherapy alone.

Starboard Value's proxy fight with Pfizer intensifies as critics target CEO Dr. Albert Bourla, alleging stock underperformance and overpaying in acquisitions. However, Pfizer's stock performance aligns with peers, and recent acquisitions show promising returns. The debate centers on Pfizer's strategic direction, with critics favoring short-term gains over long-term growth.

Bispecific antibodies, with two separate targets, are poised to replace Keytruda as the immunotherapy backbone of choice in cancer treatment by 2028. These antibodies offer benefits such as specificity, cooperative binding, and enhanced T cell engagement, potentially improving outcomes over traditional drug combinations. Over 100 bispecifics are in clinical development, with companies like AstraZeneca, BioNTech, and Summit Therapeutics leading the charge. The global market for bispecific antibodies is expected to grow significantly, reaching $485 billion in the next decade.

A personalized dose-escalated radiotherapy (RT) strategy for bladder cancer showed low severe late toxicity and survival rates comparable to cystectomy, according to a randomized trial. Only one case of grade ≥3 late toxicity occurred among 114 patients treated with dose-escalated adaptive RT (DART), with 2-year overall survival at 80% for DART and 77% for standard RT. The study highlights the potential of personalized RT to offer a more effective treatment option for bladder cancer.